NPIL Pharma, the custom manufacturing business of Nicholas Piramal India, is planning an additional investment of $4 million to upgrade its early phase drug development plant at its Ennore plant in Tamil Nadu to meet the existing demand.The company has lined up a package of four projects which includes commissioning of a new process safety lab, upgradation of existing pilot plant, adding new eight reactors with 12,000 litres capacity to the pilot plant and setting up of a new analytical laboratory, said NPIL Pharma sources.'This investment expands our early phase pilot plant and sciencecapabilities in India. With more potential for further development, the Chennai plant will be a key compliment to our European early phase facilities in Morepath and Huddersfield, UK and at our site in Ontario, Canada' said Veronica Scherrer-Pangka, president, NPIL Pharma's Pharma Development and Scale Up (PDS) business unit.NPIL Pharma, one among the top ten pharmaceutical contract manufacturing firms in the world with revenues of about $250 million, has over 200 scientists employed at Chennai, Canada and at Morepath, UK, which NPIL acquired about two years ago.
